Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM-CARE: Radioembolization + CisGem + Durvalumab in unresectable intrahepatic cholangiocarcinoma
2024-516498-57-00Phase 2Authorised
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Nov 2024
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, cisplatin and gemcitabine in intrahepatic cholangiocarcinoma (ICC), sponsored by IRCCS Ospedale San Raffaele. Primary endpoints: Overall response rate (ORR) at 6 months by mRECIST and Safety profile. Planned start Nov 2024; status: authorised.
02
Drugs
durvalumabcisplatingemcitabine
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on 2024-516498-57-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516498-57-00.